The global market for incretin-based therapeutics is expected to reach $22.8 billion by 2019
(PRWEB) April 08, 2015
Wellesley, Mass., April 08, 2015 – BCC Research (http://www.bccresearch.com) reveals in its new report on incretin-based therapeutics that diabetes, connected to obesity, is and has been on the rise globally, and new treatments are being developed and used to deal with the varying types and stages. It is a chronic disease whereby blood sugar cannot be effectively regulated because the pancreas does not produce enough insulin or the body cannot effectively use insulin.
According to the American Diabetes Association, 29.1 million Americans — 21 million of who were diagnosed and 8.1 million of who were undiagnosed — had diabetes in 2012, with the vast majority (approximately 90%) having Type 2 diabetes. The World Health Organization (WHO) projects deaths from diabetes to double globally from 2005 to 2030 in part due to increasing rates of obesity around the world. Given that half of diabetes patients — 90% of whom have Type 2 diabetes that may or may not require insulin — do not have adequate control over their blood sugar despite taking medications, a need exists for improved therapies.
Despite the numbers of diabetics and treatments, nearly 50% of patients with this condition fail to meet their glycemic target. To counteract this situation, incretin-based therapies are designed to further provide glycemic control for diabetics when diet, exercise and possibly a first-line therapy such as metformin are not adequate. They can be stand-alone treatments that, in some cases, even delay the start of insulin or reduce the need for it, and can also augment actual insulin therapy itself or other medications such as metformin.
The field of incretin-based therapies, also called incretin mimetics or incretin enhancers, has moved in the span of the last decade to be at the forefront of glycemic control in diabetes patients worldwide. “The prescription volume for incretin-based therapies has been steadily rising, particularly because so many diabetes patients are failing to reach goals for blood sugar levels (HbA1c, glycated hemoglobin expressed as either HbA1c or A1c),” says BCC Research analyst Kim Lawson. “Beyond glycemic control, incretin-based therapies, particularly GLP-1 receptor agonists, offer weight loss promotion and possibly cardioprotective attributes.”
Incretin-Based Drugs: Markets for Diabetes Therapies and Developing Treatments includes the growth potential for incretin-based therapies over a five-year period from 2014 through 2019. The key objective is to present a comprehensive analysis of the current therapy technology and drug development market and its future direction, with the aim to first define and classify that technology as it pertains to therapeutics.
Editors and reporters who wish to speak with the analyst should contact Steven Cumming at email@example.com.
About BCC Research
BCC Research publishes market research reports that make organizations worldwide more profitable with intelligence that drives smart business decisions. These reports cover today's major industrial and technology sectors, including emerging markets. For more than 40 years we've helped customers identify new market opportunities with accurate and reliable data and insight, including market sizing, forecasting, industry overviews, and identification of significant trends and key market participants. We partner with analysts who are experts in specific areas of industry and technology, providing unbiased measurements and assessments of global markets. Recently selected as the world’s greatest market research company, BCC Research is a unit of Eli Global, LLC. Visit our website at http://www.bccresearch.com. Contact us: (+1) 781-489-7301 (U.S. Eastern Time), or email firstname.lastname@example.org